Median progression-free survival in the elotuzumab group was 19.4 months , versus 14.9 months in the control group ( hazard ratio for progression or death in the elotuzumab group , 0.70 ; 95 % confidence interval , 0.57 to 0.85 ; P < 0.001 ) .